Abstract:
Lung cancer is the leading cause of cancer death worldwide. Significant advancements have been observed in the thera -py for non-small cell lung cancer (NSCLC). With constant extension of new awareness regarding the histopathology of lung cancer, ho-mologous chemotherapeutic regimens have been developed on the basis of histopathological sub-typing methods. With developments in molecular biology, driving gene mutations during tumorigenesis and progression have been discovered. A series of targeted drugs for various molecular subtypes has also been investigated and developed on the basis of these mutations. This review summarizes recently published clinical outcomes on the management of advanced NSCLC and strategies to apply drugs in clinical treatments.